These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7761669)

  • 41. Effects of recombinant human erythropoietin and exercise training on exercise capacity in hemodialysis patients.
    Akiba T; Matsui N; Shinohara S; Fujiwara H; Nomura T; Marumo F
    Artif Organs; 1995 Dec; 19(12):1262-8. PubMed ID: 8967886
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Erythropoietin, aluminum and renal anemia].
    Schaefer M; Heidland A
    Dtsch Med Wochenschr; 1990 Jun; 115(22):878-9. PubMed ID: 2347300
    [No Abstract]   [Full Text] [Related]  

  • 43. Recombinant human erythropoietin therapy. Part I: clinical issues.
    Semin Nephrol; 1989 Mar; 9(1 Suppl 1):1-34. PubMed ID: 2928605
    [No Abstract]   [Full Text] [Related]  

  • 44. Haemodialysis efficiency after long-term treatment with recombinant human erythropoietin.
    Casati S; Campise M; Crepaldi M; Lobo J; Graziani G; Ponticelli C
    Nephrol Dial Transplant; 1989; 4(8):718-20. PubMed ID: 2510080
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recombinant human erythropoietin and high flux haemodiafiltration.
    Lippi A; Rindi P; Baronti R; Caprioli R; Favilla G; Palmarini D; Cioni L
    Nephrol Dial Transplant; 1995; 10 Suppl 6():51-4. PubMed ID: 8524496
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Investigation of the influenza-like symptoms associated with recombinant human erythropoietin therapy.
    Takemasa A; Yorioka N; Yamakido M
    J Int Med Res; 1997; 25(3):127-34. PubMed ID: 9178144
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Early and late effects of erythropoietin on glucose metabolism in maintenance hemodialysis patients.
    Allegra V; Mengozzi G; Martimbianco L; Vasile A
    Am J Nephrol; 1996; 16(4):304-8. PubMed ID: 8739283
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A pharmacodynamic model of erythropoietin therapy for uremic anemia.
    Uehlinger DE; Gotch FA; Sheiner LB
    Clin Pharmacol Ther; 1992 Jan; 51(1):76-89. PubMed ID: 1732079
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Improved immunoglobulin production in dialysis patients treated with recombinant erythropoietin.
    Schaefer RM; Paczek L; Berthold G; Gilge U; Heidland A
    Int J Artif Organs; 1992 Apr; 15(4):204-8. PubMed ID: 1587641
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term persistence of improvement of renal anaemia in spite of discontinued erythropoietin treatment.
    Wiecek A; Kokot F; Marcinkowski W
    Nephron; 1995; 69(4):489-90. PubMed ID: 7777122
    [No Abstract]   [Full Text] [Related]  

  • 51. [Erythropoietin: current aspects and prospects].
    Allegra A; Buemi M; Corica F; Giacobbe MS; Frisina N; Ceruso D
    Recenti Prog Med; 1989 Oct; 80(10):531-6. PubMed ID: 2690220
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Normalization of hematocrit with recombinant human erythropoietin in chronic hemodialysis patients does not fully improve their exercise tolerance abilities.
    Suzuki M; Tsutsui M; Yokoyama A; Hirasawa Y
    Artif Organs; 1995 Dec; 19(12):1258-61. PubMed ID: 8967885
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fetal proteins and chronic treatment with low-dose erythropoietin.
    Bellizzi V; de Nicola L; Ames P; Libertino R; Terracciano V; Cianciaruso B
    J Lab Clin Med; 1997 Feb; 129(2):193-9. PubMed ID: 9016855
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Efficacy of recombinant human erythropoietin (rhuEPO) in treatment of anemia in patients with myelodysplastic syndrome].
    Wiecek A; Chudek J; Nieszporek T; Kokot F
    Pol Arch Med Wewn; 1992 Dec; 88(6):451-7. PubMed ID: 1300567
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical experience of recombinant human erythropoietin in uremic children: report of three cases.
    Chuang FR; Wu MS; Leu ML; Huang CC
    Changgeng Yi Xue Za Zhi; 1996 Mar; 19(1):71-6. PubMed ID: 8935379
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Drug delivery optimization through Bayesian networks.
    Bellazzi R
    Proc Annu Symp Comput Appl Med Care; 1992; ():572-8. PubMed ID: 1482938
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of erythropoietin administration in uremia.
    Gurland HJ; Samtleben W; Schmidt B
    Contrib Nephrol; 1989; 70():172-7. PubMed ID: 2670428
    [No Abstract]   [Full Text] [Related]  

  • 58. L-Carnitine effects on anemia in uremic rats treated with erythropoietin.
    Azzadin A; Wollny T; Pawlak R; Malyszko JS; Malyszko J; Myśliwiec M; Buczko W
    Nephron; 1999; 83(4):370-1. PubMed ID: 10575305
    [No Abstract]   [Full Text] [Related]  

  • 59. Effects of rHuEPO therapy on exercise capacity in hemodialysis patients with coronary artery disease.
    Hase H; Imamura Y; Nakamura R; Inishi Y; Machii K; Yamaguchi T
    Jpn Circ J; 1993 Feb; 57(2):131-7. PubMed ID: 8450597
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Effects of fractional or massive doses of exogenous ESF in uremic patients].
    Lamperi S; Fiorio P
    Boll Soc Ital Biol Sper; 1976 Dec; 52(23):1978-84. PubMed ID: 1027470
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.